Wisconsin Division of Public Health Disease Surveillance Manual (EpiNet, February 2005)
I. IDENTIFICATION
A. CLINICAL DESCRIPTION: Invasive disease due to Haemophilus influenzae that may produce any of several clinical syndromes, including meningitis, bacteremia, epiglottitis, or pneumonia.
B. REPORTING CRITERIA: Clinical diagnosis or laboratory confirmation.
C. LABORATORY CRITERIA FOR DIAGNOSIS:
- Isolation of Haemophilus influenzae from a normally sterile site (blood, CSF, or less commonly, joint, pleural, or pericardial fluid).
D. WISCONSIN CASE DEFINITION: A clinically compatible illness that is laboratory confirmed.
II. ACTIONS REQUIRED / PREVENTION MEASURES
A. WISCONSIN DISEASE SURVEILLANCE CATEGORY I: Report IMMEDIATELY BY TELEPHONE to the patient's local health officer upon identification of a case or suspected case. Complete and mail an Acute and Communicable Disease Case Report (DPH 4151) to the local health officer within 24 hours.
B. EPIDEMIOLOGY REPORTS REQUIRED:
1. Acute and Communicable Diseases Case Report (DPH 4151)
2. Vaccine History and Serogroup Worksheet.C. PUBLIC HEALTH INTERVENTIONS:
- Determine the serotype of Haemophilus influenzae isolated.
- Investigation of known and suspect contacts.
- Chemoprophylaxis or observation of contacts as indicated.
- Evaluate Haemophilus influenzae type b vaccine status of close contacts and update as appropriate.
III. CONTACTS FOR CONSULTATION
A. BCDP / COMMUNICABLE DISEASE EPIDEMIOLOGY SECTION: (608) 267-7321.
B. REGIONAL STAFF: See Epinet Introduction: “REGIONAL OFFICE CONTACTS”.
C. WSLH / BACTERIOLOGY: (608) 263-3421.
IV. RELATED REFERENCES
1. “Haemophilus influenza Type B”, DPH Disease Fact Sheet Series: View a list of all current Communicable Disease Fact Sheets
2. Heymann DL, ed. HEMOPHILUS MENINGITIS. In: Control of Communicable Diseases Manual. 18 th ed. Washington , DC : American Public Health Association, 2004:366-368
3. Pickering LK, ed. Haemophilus influenzae Infections. In: Red Book: 2003 Report of the Committee on Infectious Diseases. 26 th ed. Elk Grove Village , IL : American Academy of Pediatrics, 2003:293-301.
4. Recommendations for use of Haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis, and Haemophilus b vaccine. Recommendations of the Advisory Committee on Immunization (ACIP). MMWR 1993; 42(RR-13): 1-13.
V. DISEASE TRENDS
Vaccine History and Serogroup Worksheet (Submit with 4151 )for the reporting of invasive Neisseria meningitidis, Haemophilusinfluenzae and Streptococcus pneumoniae
Patient Name: _________________________________________ Date of Birth:____/____/________
Person completing form: ___________________________ Phone: (_____)_____-__________
A. Type of infection caused by organism (check all that apply):
____ Primary bacteremia ____ Meningitis ____ Septic arthritis ____ Epiglottitis
____ Peritonitis ____ Pericarditis ____ Other (_______________________)
Specimen source from which organism was isolated (check all that apply):
____ Cerebrospinal fluid (CSF) ____ Blood ____ Other sterile site (_______________)
____ No organism isolated (suspect case)
Date of collection of first positive culture: _____/_____/_______
Does the patient have any of the following (circle)?
_____ Cochlear implant _____ Permanent shunt _____ Facial fracture
Choose the causative organism below and provide additional information:
____ 1. Haemophilus influenzae:
Serotype:
____ Serotype b* _____ Other serotype (specify ______) ____ Non-typeable
____ Serotyping unknown, pending or not tested
*Did patient receive the Haemophilus influenzae (Hib) vaccine? ____ Yes ____ No
If yes, complete the following information:
Dose Date Received Vaccine Manufacturer Lot #
1 _____/_____/________ ______________/_______________/__________
2 _____/_____/________ _____________ /_______________/__________
3 _____/_____/________ ______________/_______________/__________
4 _____/_____/________ ______________/_______________/__________
_____ 2.Neisseria meningitidis:
Serotype: ____ A ____ B _____ C ____ Y ____ W-135
____ Not typeable ____ Serotyping unknown, pending or not tested
Did the patient receive the Neisseria meningitidis vaccine? ____ Yes ____ No
If yes, complete the following information:
Date Received Vaccine Manufacturer Lot #
_____/_____/________ ______________/_______________/__________
_____ 3.Streptococcus pneumoniae:
Did patient receive the PCV7 (Prevnar®) vaccine? ____ Yes ____ No
Dose + Date Received Vaccine Manufacturer Lot #
1 _____/_____/________ ______________/_______________/__________
2 _____/_____/________ _____________ /_______________/__________
3 _____/_____/________ ______________/_______________/__________
4 _____/_____/________ ______________/_______________/__________
+ 1-4 doses required depending on age of child at time of vaccination .
Did patient receive the “pneumococcal” vaccine? ____ Yes ____ No
Was this a revaccination? ____ Yes ____ No
Date Received Vaccine Manufacturer Lot #
_____/_____/________ ______________/_________________/____________
_____/_____/________ ______________/_________________/____________
Submitted by: _____________________________________ County: ____________________
Telephone #: (____)____________________ Date: _____/_____/________
NOTE: Serotype testing are performed at the Wisconsin State Laboratory of Hygiene (WSLH) at no cost to the submitting laboratory. It is strongly encouraged that all invasive isolates of Neisseria meningitidis and Haemophilus influenzae be sent to the WSLH for serotyping. Serotyping results are also needed for state and national surveillance programs. Transport costs are covered through the Invasive Bacteria Laboratory Surveillance (IBLS) program. If your laboratory does not participate in IBLS, please contact the Invasive Bacteria Coordinator to learn how shipping costs for relevant organisms can be paid through the IBLS program.
Streptococcus pneumoniae isolates, from children under 5 years of age, should also be sent to the WSLH. Isolates will be forwarded to the Centers for Disease Control and Prevention for serotyping to identify potential vaccine failures.
